07:33 AM EDT, 10/11/2024 (MT Newswires) -- CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million.

Underwriters have been granted a 30-day option to buy up to about 1 million additional shares.

Shares of the biotechnology company are expected to begin trading on Nasdaq this Friday, under the ticker symbol, "CAMP." The IPO is set to close Oct. 15.